The role of APOBEC3B in chondrosarcoma

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1867-1872

  Jin, Zhe ^a   Han, Ya Xin ^a   Han, Xiao Rui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

APOBEC3B; Apoptosis; Chondrosarcoma; Proliferation; RUNX3

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; CASPASE 3; CASPASE 8; CASPASE 9; CELL PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; RUNX3 PROTEIN, HUMAN;

ADULT; AGED; APOBEC3B GENE; APOPTOSIS; ARTICLE; CANCER RISK; CHINESE; CHONDROSARCOMA; CHONDROSARCOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POPULATION RESEARCH; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RUNX3 GENE; SARCOMA CELL; TISSUE LEVEL; ASIAN CONTINENTAL ANCESTRY GROUP; BONE TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; APOPTOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CELL LINE, TUMOR; CHONDROSARCOMA; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CYTIDINE DEAMINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84907281044     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3437     Document Type: Article

References (21)

1. Terek RM, Schwartz GK, Devaney K, et al: Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 16: 585-590, 1998.
2. Hiraoka K, Zenmyo M, Komiya S, et al: Relationship of p21(waf1/cip1) and differentiation in chondrosarcoma cells. Virchows Arch 440: 285-290, 2002.
3. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, et al: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 69: 6216-6222, 2009.
4. DeLaney TF, Liebsch NJ, Pedlow FX, et al: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74: 732-739, 2009.
5. Goila-Gaur R and Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5: 51, 2008.
6. Heidmann T, Heidmann O and Nicolas JF: An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci USA 85: 2219-2223, 1988.
7. Macduff DA and Harris RS: Directed DNA deamination by AID/APOBEC3 in immunity. Curr Biol 16: R186-R189, 2006.
8. Conticello SG: The AID/APOBEC family of nucleic acid mutators. Genome Biol 9: 229, 2008.
9. Burns MB, Lackey L, Carpenter MA, et al: APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494: 366-370, 2013.
10. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL and Harris RS: Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274-4284, 2010.
11. Burns MB, Temiz NA and Harris RS: Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45: 977-983, 2013.
12. Kim DW, Kim KO, Shin MJ, et al: siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 8: 28, 2009.
13. Nishida K, Furumatsu T, Takada I, et al: Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-Activated receptor-α. Br J Cancer 86: 1303-1309, 2002.
14. Jin Z, Han YX and Han XR: Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma. J Mol Histol 44: 645-652, 2013.
15. Xu R, Zhang X, Zhang W, Fang Y, Zheng S and Yu XF: Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology 46: 1810-1820, 2007.
16. Chiu YL and Greene WC: The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317-353, 2008.
17. Han YX and Liang DY: The role of the tumor suppressor RUNX3 in giant cell tumor of the bone. Int J Oncol 40: 673-678, 2011.
18. Holmes RK, Koning FA, Bishop KN and Malim MH: APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595, 2007.
19. Iwatani Y, Chan DS, Wang F, et al: Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35: 7096-7108, 2007.
20. Mbisa JL, Barr R, Thomas JA, et al: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81: 7099-7110, 2007.
21. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499: 214-218, 2013.